Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer

Shin Ebara, Yoshihisa Katayama, Ryuta Tanimoto, Kohei Edamura, Hiroyuki Nose, Daisuke Manabe, Tomoko Kobayashi, Yasuyuki Kobayashi, Makoto Kobuke, Mitsuhiro Takemoto, Takashi Saika, Yasutomo Nasu, Susumu Kanazawa, Hiromi Kumon

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treatedusing iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment's efficacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classified as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of difficulty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the first month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and effective for localized prostate cancer within short-term follow up. Copyright

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalActa Medica Okayama
Volume62
Issue number1
Publication statusPublished - Feb 2008

Fingerprint

Brachytherapy
Prostate-Specific Antigen
Iodine
Seed
Prostatic Neoplasms
Seeds
Dentistry
Biopsy
Medicine
Ultrasonics
Imaging techniques
Radiation
Prostate
School Dentistry
Pharmaceutical Preparations
Prostatitis
Urination
Urinary Incontinence
Ultrasonography
Guidelines

Keywords

  • Brachytherapy
  • Localized prostate cancer
  • Prostate specific antigen
  • Urinary morbidity

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer. / Ebara, Shin; Katayama, Yoshihisa; Tanimoto, Ryuta; Edamura, Kohei; Nose, Hiroyuki; Manabe, Daisuke; Kobayashi, Tomoko; Kobayashi, Yasuyuki; Kobuke, Makoto; Takemoto, Mitsuhiro; Saika, Takashi; Nasu, Yasutomo; Kanazawa, Susumu; Kumon, Hiromi.

In: Acta Medica Okayama, Vol. 62, No. 1, 02.2008, p. 9-13.

Research output: Contribution to journalArticle

Ebara, S, Katayama, Y, Tanimoto, R, Edamura, K, Nose, H, Manabe, D, Kobayashi, T, Kobayashi, Y, Kobuke, M, Takemoto, M, Saika, T, Nasu, Y, Kanazawa, S & Kumon, H 2008, 'Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer', Acta Medica Okayama, vol. 62, no. 1, pp. 9-13.
Ebara, Shin ; Katayama, Yoshihisa ; Tanimoto, Ryuta ; Edamura, Kohei ; Nose, Hiroyuki ; Manabe, Daisuke ; Kobayashi, Tomoko ; Kobayashi, Yasuyuki ; Kobuke, Makoto ; Takemoto, Mitsuhiro ; Saika, Takashi ; Nasu, Yasutomo ; Kanazawa, Susumu ; Kumon, Hiromi. / Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer. In: Acta Medica Okayama. 2008 ; Vol. 62, No. 1. pp. 9-13.
@article{206d1c5bbc2544efa337e1bb61db8b79,
title = "Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer",
abstract = "From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treatedusing iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment's efficacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classified as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7{\%}) complained of difficulty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the first month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and effective for localized prostate cancer within short-term follow up. Copyright",
keywords = "Brachytherapy, Localized prostate cancer, Prostate specific antigen, Urinary morbidity",
author = "Shin Ebara and Yoshihisa Katayama and Ryuta Tanimoto and Kohei Edamura and Hiroyuki Nose and Daisuke Manabe and Tomoko Kobayashi and Yasuyuki Kobayashi and Makoto Kobuke and Mitsuhiro Takemoto and Takashi Saika and Yasutomo Nasu and Susumu Kanazawa and Hiromi Kumon",
year = "2008",
month = "2",
language = "English",
volume = "62",
pages = "9--13",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "1",

}

TY - JOUR

T1 - Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer

AU - Ebara, Shin

AU - Katayama, Yoshihisa

AU - Tanimoto, Ryuta

AU - Edamura, Kohei

AU - Nose, Hiroyuki

AU - Manabe, Daisuke

AU - Kobayashi, Tomoko

AU - Kobayashi, Yasuyuki

AU - Kobuke, Makoto

AU - Takemoto, Mitsuhiro

AU - Saika, Takashi

AU - Nasu, Yasutomo

AU - Kanazawa, Susumu

AU - Kumon, Hiromi

PY - 2008/2

Y1 - 2008/2

N2 - From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treatedusing iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment's efficacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classified as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of difficulty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the first month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and effective for localized prostate cancer within short-term follow up. Copyright

AB - From January 2004 to March 2007, 308 patients with clinically localized prostate cancer were treatedusing iodine-125 (125I) seed implantation (permanent brachytherapy) at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. We evaluated the treatment's efficacy and morbidity in 300 prostate cancer patients who were followed up for more than 1 month after brachytherapy. Based on the National Comprehensive Cancer Network (NCCN) guidelines, patients with a prostate volume of less than 40 ml in transrectal ultrasound imaging were classified as low or intermediate risk. The median patient age was 67 years (range 50 to 79 years), the median prostate-specific antigen (PSA) value before biopsy was 6.95 ng/ml (range 1.13 to 24.7 ng/ml), and the median prostate volume was 24.33 ml (range 9.3 to 41.76 ml). The median follow-up was 18 months (range 1 to 36 months) and the PSA levels decreased in almost all patients after brachytherapy. Although 194 of 300 patients (64.7%) complained of difficulty in urination, pollakisuria/urgency, miction pain, and/or urinary incontinence, all of which might be associated with radiation prostatitis during the first month after brachytherapy, these symptoms gradually improved. 125I seed implantation brachytherapy is safe and effective for localized prostate cancer within short-term follow up. Copyright

KW - Brachytherapy

KW - Localized prostate cancer

KW - Prostate specific antigen

KW - Urinary morbidity

UR - http://www.scopus.com/inward/record.url?scp=41549139341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41549139341&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 9

EP - 13

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 1

ER -